Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 1073968-64-5 | MDL No. : | MFCD09026771 |
Formula : | C9H11BrClN | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | RPHAEDCEIPCYBX-UHFFFAOYSA-N |
M.W : | 248.55 | Pubchem ID : | 46238398 |
Synonyms : |
|
Num. heavy atoms : | 12 |
Num. arom. heavy atoms : | 6 |
Fraction Csp3 : | 0.33 |
Num. rotatable bonds : | 0 |
Num. H-bond acceptors : | 0.0 |
Num. H-bond donors : | 1.0 |
Molar Refractivity : | 61.01 |
TPSA : | 12.03 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | Yes |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | Yes |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -5.13 cm/s |
Log Po/w (iLOGP) : | 0.0 |
Log Po/w (XLOGP3) : | 3.79 |
Log Po/w (WLOGP) : | 3.04 |
Log Po/w (MLOGP) : | 3.07 |
Log Po/w (SILICOS-IT) : | 3.12 |
Consensus Log Po/w : | 2.6 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 1.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -4.14 |
Solubility : | 0.0181 mg/ml ; 0.0000727 mol/l |
Class : | Moderately soluble |
Log S (Ali) : | -3.74 |
Solubility : | 0.0456 mg/ml ; 0.000183 mol/l |
Class : | Soluble |
Log S (SILICOS-IT) : | -4.14 |
Solubility : | 0.0181 mg/ml ; 0.0000728 mol/l |
Class : | Moderately soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 2.0 |
Synthetic accessibility : | 1.88 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P280-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302-H315-H319-H332-H335 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
66% | To a solution of <strong>[1073968-64-5]5-bromo-1,2,3,4-tetrahydroquinoline hydrochloride</strong> (0.90 g, 3.621 mmol) in dichloromethane (6 mL), N,N-dimethylaminopyridine (0.044 g, 0.362 mmol) and triethylamine (1.06 mL, 7.6 mmol) were added. The mixture was stirred for 30 min at room temperature, then di-tert-butyl dicarbonate (0.873 mL, 3.802 mmol) was added portionwise. The solution was stirred at room temperature overnight. The mixture was diluted with ethyl acetate. The organic layer was washed with water and brine, filtered, and the filtrate was dried and concentrated. The mixture was purified by flash chromatography (SiO2, heptane-ethylacetate gradient). Pure fractions were combined and concentrated. The residue was dried under reduced pressure to yield tert-butyl 5-bromo-3,4-dihydroquinoline-1(2H)-carboxylate, cpd 127a (749 mg, 66% yield). MS m/z 213.9 (M+H-tBu)+. |
A200491[ 114744-50-2 ]
5-Bromo-1,2,3,4-tetrahydroquinoline
Reason: Free-Salt
[ 114744-50-2 ]
5-Bromo-1,2,3,4-tetrahydroquinoline
Similarity: 0.98
[ 1195901-53-1 ]
7-Bromo-1,2,3,4-tetrahydroquinoline hydrochloride
Similarity: 0.94
[ 114744-51-3 ]
7-Bromo-1,2,3,4-tetrahydroquinoline
Similarity: 0.92
[ 22190-35-8 ]
6-Bromo-1,2,3,4-tetrahydroquinoline
Similarity: 0.91
[ 114744-50-2 ]
5-Bromo-1,2,3,4-tetrahydroquinoline
Similarity: 0.98
[ 1195901-53-1 ]
7-Bromo-1,2,3,4-tetrahydroquinoline hydrochloride
Similarity: 0.94
[ 114744-51-3 ]
7-Bromo-1,2,3,4-tetrahydroquinoline
Similarity: 0.92
[ 22190-35-8 ]
6-Bromo-1,2,3,4-tetrahydroquinoline
Similarity: 0.91
[ 1187830-63-2 ]
6-Bromo-4,4-dimethyl-1,2,3,4-tetrahydroquinoline hydrochloride
Similarity: 0.86